Table 1.
Demographic and clinical characteristics of recruited participants.
| Variables | Qiaokou cohort (training set) | P* | Caidian cohort (validation set) | P* | P † | ||
|---|---|---|---|---|---|---|---|
| ATB (n=54) | LTBI (n=62) | ATB (n=43) | LTBI (n=41) | ||||
| Age, years | 55 (35-65) | 53 (32-66) | 0.835 | 49 (29-57) | 49 (37-60) | 0.45 | 0.102 |
| Sex, male, % | 35 (64.81%) | 36 (58.06%) | 0.457 | 30 (69.77%) | 28 (68.29%) | 0.884 | 0.253 |
| Underlying condition or illness | |||||||
| Diabetes mellitus | 14 (25.93%) | 9 (14.52%) | 0.124 | 9 (20.93%) | 5 (12.2%) | 0.283 | 0.57 |
| Solid tumor | 3 (5.56%) | 3 (4.84%) | 0.805 | 3 (6.98%) | 2 (4.88%) | 0.956 | 0.94 |
| Hematological malignancy | 1 (1.85%) | 0 (0%) | 0.466 | 1 (2.33%) | 0 (0%) | 1 | 1 |
| Virus hepatitis or cirrhosis | 6 (11.11%) | 3 (4.84%) | 0.362 | 7 (16.28%) | 4 (9.76%) | 0.376 | 0.214 |
| Heart disease | 5 (9.26%) | 3 (4.84%) | 0.569 | 3 (6.98%) | 2 (4.88%) | 0.956 | 0.789 |
| End-stage renal disease | 4 (7.41%) | 1 (1.61%) | 0.283 | 2 (4.65%) | 1 (2.44%) | 0.966 | 0.918 |
| Organ transplantation | 2 (3.7%) | 0 (0%) | 0.215 | 1 (2.33%) | 0 (0%) | 1 | 1 |
| Immunosuppressive condition‡ | 6 (11.11%) | 4 (6.45%) | 0.575 | 5 (11.63%) | 4 (9.76%) | 0.94 | 0.618 |
| Positive culture for MTB | 48 (88.89%) | N/A | N/A | 40 (93.02%) | N/A | N/A | N/A |
| Positive GeneXpert MTB/RIF | 42 (77.78%) | N/A | N/A | 31 (72.09%) | N/A | N/A | N/A |
ATB, active tuberculosis; LTBI, latent tuberculosis infection; MTB, Mycobacterium tuberculosis; N/A, not applicable. *Comparisons were performed between ATB and LTBI groups using Mann-Whitney U test, Chi-square test, or Fisher’s exact test. †Comparisons were performed between Qiaokou and Caidian cohorts using Mann-Whitney U test, Chi-square test, or Fisher’s exact test. ‡Patients who underwent chemotherapy or took immunosuppressants within 3 months. Data were presented as medians (25th-75th) or numbers (percentages).